CA3105763A1 - Immunogenic composition for paratuberculosis - Google Patents

Immunogenic composition for paratuberculosis Download PDF

Info

Publication number
CA3105763A1
CA3105763A1 CA3105763A CA3105763A CA3105763A1 CA 3105763 A1 CA3105763 A1 CA 3105763A1 CA 3105763 A CA3105763 A CA 3105763A CA 3105763 A CA3105763 A CA 3105763A CA 3105763 A1 CA3105763 A1 CA 3105763A1
Authority
CA
Canada
Prior art keywords
polypeptide
amino acid
seq
acid sequence
map
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3105763A
Other languages
English (en)
French (fr)
Inventor
John Hermon-Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HAV Vaccines Ltd
Original Assignee
HAV Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HAV Vaccines Ltd filed Critical HAV Vaccines Ltd
Publication of CA3105763A1 publication Critical patent/CA3105763A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3105763A 2018-07-11 2019-07-10 Immunogenic composition for paratuberculosis Pending CA3105763A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1811382.9 2018-07-11
GBGB1811382.9A GB201811382D0 (en) 2018-07-11 2018-07-11 Vaccine
PCT/GB2019/051933 WO2020012177A1 (en) 2018-07-11 2019-07-10 Immunogenic composition for paratuberculosis

Publications (1)

Publication Number Publication Date
CA3105763A1 true CA3105763A1 (en) 2020-01-16

Family

ID=63273113

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3105763A Pending CA3105763A1 (en) 2018-07-11 2019-07-10 Immunogenic composition for paratuberculosis

Country Status (14)

Country Link
US (2) US12186382B2 (enExample)
EP (1) EP3820507A1 (enExample)
JP (2) JP2021524485A (enExample)
KR (1) KR20210033490A (enExample)
CN (1) CN113329765A (enExample)
AU (1) AU2019301899A1 (enExample)
BR (1) BR112021000312A2 (enExample)
CA (1) CA3105763A1 (enExample)
GB (1) GB201811382D0 (enExample)
IL (1) IL280070B2 (enExample)
MA (1) MA53131A (enExample)
MX (1) MX2020013924A (enExample)
SG (1) SG11202100120TA (enExample)
WO (1) WO2020012177A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700487D0 (en) * 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
WO2026041756A1 (en) 2024-08-21 2026-02-26 Hav Vaccines Limited Treatment of crohn's disease by mycobacterium avium subsp. paratuberculosis agent

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5225324A (en) 1987-04-24 1993-07-06 Bioscience International, Inc. Diagnostics for mycobacteria in public health, medical, and veterinary practice
GB8709803D0 (en) 1987-04-24 1987-05-28 Mcfadden J J Treatment of crohn's disease &c
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JPH07505283A (ja) 1992-03-20 1995-06-15 ベイラー・カレッジ・オブ・メディシン Ｄｎａトランスポーター系および使用方法
AU682308C (en) 1992-04-03 2006-08-17 Regents Of The University Of California, The Self-assembling polynucleotide delivery system
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
GB9526178D0 (en) 1995-12-21 1996-02-21 Taylor John Hermon Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy
GB9806093D0 (en) 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
ATE466876T1 (de) 2005-08-09 2010-05-15 Hav Vaccines Ltd Immunogene konstrukte
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
EP2710151A4 (en) 2011-05-19 2014-12-10 Univ Central Florida Res Found MICROBEND DETECTION BY HYBRIDIZATION OF MAGNETIC RELAXATION NANOSENSORS
WO2014016737A1 (en) 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
JP2016513078A (ja) * 2013-01-28 2016-05-12 ダンマルクス テクニスケ ウニベルシテット 一段階または多段階のトリ型結核菌亜種副結核症サブユニット・ワクチン
GB201700487D0 (en) * 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic

Also Published As

Publication number Publication date
US20210338791A1 (en) 2021-11-04
IL280070A (en) 2021-03-01
JP2021524485A (ja) 2021-09-13
IL280070B1 (en) 2023-12-01
US20250152691A1 (en) 2025-05-15
IL280070B2 (en) 2024-04-01
MX2020013924A (es) 2021-03-02
CN113329765A (zh) 2021-08-31
KR20210033490A (ko) 2021-03-26
MA53131A (fr) 2021-05-19
SG11202100120TA (en) 2021-02-25
JP2024153666A (ja) 2024-10-29
GB201811382D0 (en) 2018-08-29
EP3820507A1 (en) 2021-05-19
WO2020012177A1 (en) 2020-01-16
AU2019301899A1 (en) 2021-01-14
BR112021000312A2 (pt) 2021-04-13
US12186382B2 (en) 2025-01-07

Similar Documents

Publication Publication Date Title
US20250152691A1 (en) Immunogenic composition for paratuberculosis
US8697856B2 (en) Plasmodium vivax hybrid circumsporozoite protein and vaccine
JP2001517069A (ja) 結核の免疫治療および診断のための化合物および方法
CA2884918C (en) Salmonid alphavirus and uses thereof
JP2002503683A (ja) 結核の免疫療法および診断のための化合物および方法
JP2003524021A (ja) 悪性中皮腫の診断および治療のための組成物および方法
JPH10179175A (ja) 新規ｍ蛋白質
US8147850B2 (en) Immunogenic constructs
JPH10165187A (ja) 新規唾液結合蛋白質
CZ2001839A3 (cs) Peptidové fragmenty toxinu B cholery nebo enterotoxinu B jako vakcinační adjuvans
WO2003005957A2 (en) Mutants of clostridium septicum alpha toxin and vaccines, antibodies, sera, and methods of treatment therewith
WO2002079247A2 (en) Intimins in the prevention or treatment of infections:ii
JPH11215989A (ja) 免疫グロブリン遺伝子スーパーファミリーのメンバー、ｐｉｇｒ−２

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240610

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260513